Tan Zachary, Chong CheeFoong, Darlow Brian, Dai Shuan
School of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Department of Ophthalmology, University of Auckland, Auckland, New Zealand Department of Ophthalmology, Greenlane Clinical Centre, Auckland, New Zealand.
Br J Ophthalmol. 2015 Jun;99(6):801-6. doi: 10.1136/bjophthalmol-2014-305913. Epub 2014 Dec 19.
To evaluate retinopathy of prematurity (ROP)-related visual impairment in New Zealand children.
22-year retrospective review of medical records of children with moderate to severe visual impairment registered with the Blind and Low Vision Education Network New Zealand. The cohort was divided into two periods (1991-2004; 2005-2012) for analysis.
232 children with ROP were treated in the study period (109 in period 1, 123 in period 2). 36 children, 63.9% of whom were of male sex, were identified with subsequent significant visual impairment (27 in period 1, 9 in period 2). The incidence of new cases of visual impairment from ROP declined from 271.6 infants/100 000 live very preterm births per annum (period 1) to 146.1 per annum (period 2). Mean gestational age and mean birth weight were comparable between the two study periods. 75% of children with visual impairment from ROP received treatment for their condition (period 1, 74.1%; period 2, 77.8%) and modalities used changed significantly over time. The modal visual outcome overall was Snellen visual acuity <6/18-6/60 (55.6%) (period 1, 51.9%; period 2, 66.7%). The proportion of children with no light perception bilaterally decreased over time (period 1, 3.7%; period 2, 0%).
There has been a reduction in the incidence of infants with significant visual impairment from ROP over time in New Zealand, likely due to progress in clinical management of ROP. Our study suggests the current ROP screening criteria of <31 weeks' gestation or <1250 g are of sufficient breadth.
评估新西兰儿童中的早产儿视网膜病变(ROP)相关视力损害情况。
对在新西兰盲人和低视力教育网络登记的中重度视力损害儿童的病历进行22年的回顾性研究。该队列分为两个时期(1991 - 2004年;2005 - 2012年)进行分析。
在研究期间,232例ROP患儿接受了治疗(第1期109例,第2期123例)。36例患儿被确定随后出现明显视力损害,其中63.9%为男性(第1期27例,第2期9例)。ROP导致的视力损害新发病例发生率从每年每100 000例极早产活产儿中的271.6例(第1期)降至每年146.1例(第2期)。两个研究时期的平均胎龄和平均出生体重具有可比性。75%的ROP相关视力损害患儿接受了相应治疗(第1期为74.1%;第2期为77.8%),且随着时间推移,所使用的治疗方式发生了显著变化。总体上,最常见的视力结果是Snellen视力<6/18 - 6/60(55.6%)(第1期为51.9%;第2期为66.7%)。双侧无光感患儿的比例随时间下降(第1期为3.7%;第2期为0%)。
随着时间推移,新西兰ROP导致明显视力损害的婴儿发生率有所下降,这可能归因于ROP临床管理方面的进展。我们的研究表明,目前胎龄<31周或出生体重<1250 g的ROP筛查标准具有足够的广度。